News Acadia, Harmony record late-stage rare disease failures Biotechs Acadia Pharma and Harmony Biosciences both suffered setbacks in phase 3 trials of drugs for rare diseases, in one case ending the programme.
News Alarm as Trump peddles unproven causes of autism Medical groups have reacted with dismay after Trump linked childhood vaccinations and use of acetaminophen to autism.
News Stealth's patience rewarded as FDA approves Barth drug After a long haul, Stealth BioTherapeutics has finally claimed FDA approval for Forzinity, the first treatment for ultra-rare disease Barth syndrome.
News COVID-19 vaccine support reined back by ACIP The CDC's vaccine committee reduced some support for COVID-19 vaccines, but did not go as far as some might have feared in limiting access.
News ACIP pushes back vote on hepatitis B vaccine ACIP has agreed to push back a vote on recommendations for a birth dose of hepatitis B vaccine, as panellists were unhappy with the proposed wording.
News Closed Loop Medicine launches digital GLP-1 dosing platform Closed Loop Medicine has launched its first product in the US, a digital tool for personalising the dose of GLP-1 weight-loss therapies.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.